Summary
Kaltura has 2 registry-verified rows in the CertReports index, last verified 17 Sep 2026. The strongest row is CSA STAR: STAR Level 1 self-assessment (CAIQ). This page is independent of the vendor’s own trust centre: dates, sources and caveats come from CertReports captures.
Reviewer brief
As of 17 Sep 2026, Kaltura is listed in the CSA STAR registry with a STAR Level 1 self-assessment (CAIQ) issued on 4 Jun 2021, with no expiry date provided. As of 17 Sep 2026, Kaltura is listed in the EU-US Data Privacy Framework registry as active, covering SW-US Certification, EU-US Certification, and UK Extension Certification, issued 12 Aug 2016 and expiring 8 Jan 2027. As of 17 Sep 2026, no public evidence found for SOC 2 for Kaltura. As of 17 Sep 2026, no public evidence found for HIPAA for Kaltura. As of 17 Sep 2026, no subprocessor evidence rows were supplied for Kaltura, so no public evidence found regarding subprocessor disclosures.
- CSA STAR: listed in registry, STAR Level 1 self-assessment (CAIQ), issued 4 Jun 2021, no expiry date, as of 17 Sep 2026.
- EU-US Data Privacy Framework: listed in registry as active (SW-US, EU-US, UK Extension Certifications), issued 12 Aug 2016, expires 8 Jan 2027, as of 17 Sep 2026.
- SOC 2 and HIPAA: no public evidence found for Kaltura as of 17 Sep 2026.
Facts only, each dated; nothing here is inferred, scored or advised. Brief generated 17 Sep 2026; it is regenerated whenever a row changes.
Among media and content vendors
2verified rows
Category median 1, across 20 indexed media and content vendors. Kaltura has more verified rows than 100 percent of them.
live streamingon-demand videovideo managementvideo platform
Compare with similar vendors
Pick your own comparisonCompliance grid
Legal artefacts
No DPA, BAA or subprocessor list has been captured from a public page yet. Registry rows above do not depend on this.
Subprocessors
No subprocessor list captured yet.
Similar vendors with evidence
Related by product tags and the Media and content category, ranked by shared tags, description similarity and overlapping evidence. Never by popularity.
